Drug Pipeline
An overview of recently approved therapies, anticipated approvals in the year to come, and strategies to help manage the pipeline More
Feature
“Drug Pipeline”
10 result(s)
Drug Pipeline
Peanut allergy is the most common of childhood food allergies — and getting more common. Research presented at the annual meeting of the American College of Allergy, Asthma and... More
Feature
Specialty
CVS Health’s three-tier specialty formulary design separates the increasingly more expensive specialty therapies into three distinct copay or coinsurance categories. Paired with... More
Briefing
Drug Pipeline
Scientific developments are altering the pace and focus of specialty drug development, while regulatory changes are shortening approval times. This poses new challenges for payors... More
Briefing
Specialty
While the launch time is uncertain, potential PAH generics could give payors greater cost control opportunities for a complex, expensive condition requiring lifelong treatment. More
Briefing
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature
Care Management
High drug costs, social stigma, complications, comorbidities, and complexity of medication regimen, make HIV a challenging disease. A whole-patient care management approach is... More
Briefing
Drug Pipeline
The market for migraine medications is ripe for growth due to a large patient population with an unmet clinical need. Four investigational medications known CGRP inhibitors will... More
Feature
Specialty
HIV drugs are a $17 billion market and the pipeline has seen dramatic shifts in recent years. Ongoing monitoring, effective utilization management, and a focus on adherence can... More
Briefing
Specialty
The specialty pipeline has many promising new drugs. The complexity and personalized nature of some medications require that they be managed under the medical benefit. More
Briefing